Editas Medicine Inc. and Bluerock Therapeutics LP have agreed to combine their respective genome editing and cell therapy technologies to discover, develop and manufacture a set of new off-the-shelf cell therapies targeting a broad array of indications. Editas will focus on oncology, including solid tumors and blood cancers, while Bluerock will work on neurology, cardiology and immunology indications. Potential products based on the approach are likely several years away. But Cindy Collins, interim CEO of Editas, said she is optimistic about their value.